Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.
暂无分享,去创建一个
Richard D Moore | J. Goedert | Jeffrey N. Martin | R. Hogg | S. Gange | J. Brooks | T. Sterling | M. Gill | M. Saag | R. Bosch | A. Collier | S. Rourke | A. Justice | M. Horberg | S. Deeks | K. Gebo | A. Rachlis | C. Benson | J. Eron | M. Kushel | M. Kitahata | B. Rodriguez | G. Kirk | M. Silverberg | L. Jacobson | M. Klein | L. Calzavara | S. Napravnik | R. McKaig | Sean B. Rourke | Margot B. Kushel | R. Mckaig | Constance A. Benson | Gregory D Kirk | Amy C. Justice | Jeffrey N. Martin | Anita R Rachlis | Timothy R. Sterling | J. T. Brooks | Lisa P. Jacobson | M. Klein | Ann C. Collier | Robert S. Hogg | M. Saag | J. J. Goedert | M. Gill | Ronald J. Bosch | Richard D. Moore | S. Gange | Joseph J Eron
[1] Michael J Silverberg,et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. , 2009, The New England journal of medicine.
[2] P. Francioli,et al. Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] Anders Karlsson,et al. Maraviroc for previously treated patients with R5 HIV-1 infection. , 2008, The New England journal of medicine.
[4] B. Gazzard,et al. Triple-class antiretroviral agent resistance in a large cohort: prevalence and clinical outcomes. , 2008, Archives of internal medicine.
[5] D. Havlir. HIV integrase inhibitors--out of the pipeline and into the clinic. , 2008, The New England journal of medicine.
[6] D. Hazuda,et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. , 2008, The New England journal of medicine.
[7] D. Pillay,et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? , 2008, The Journal of antimicrobial chemotherapy.
[8] M. Colafigli,et al. Genotypic resistance profile and clinical progression of treatment-experienced HIV type 1-infected patients with virological failure. , 2008, AIDS research and human retroviruses.
[9] B. Gazzard,et al. Changes in Outcome of Persons Initiating Highly Active Antiretroviral Therapy at a CD4 Count Less Than 50 Cells/mm3 , 2008, Journal of acquired immune deficiency syndromes.
[10] B. Gazzard,et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study , 2007, The Lancet.
[11] H. Sørensen,et al. Genotypic Drug Resistance and Long-Term Mortality in Patients with Triple-Class Antiretroviral Drug Failure , 2007, Antiviral therapy.
[12] R. Haubrich,et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.
[13] J. Eron,et al. Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients , 2007, AIDS.
[14] Richard D Moore,et al. Cohort profile: the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD). , 2007, International journal of epidemiology.
[15] Jonathan A C Sterne,et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.
[16] J. Gatell,et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. , 2006, Archives of internal medicine.
[17] P. Harrigan,et al. Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.
[18] C. Sabin,et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers , 2006, AIDS.
[19] P. Narciso,et al. Multiple drug class-wide resistance associated with poorer survival after treatment failure in a cohort of HIV-infected patients , 2005, AIDS.
[20] Richard D Moore,et al. An Improvement in Virologic Response to Highly Active Antiretroviral Therapy in Clinical Practice From 1996 Through 2002 , 2005, Journal of acquired immune deficiency syndromes.
[21] A. Mocroft,et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. , 2004, The Journal of infectious diseases.
[22] Richard D Moore,et al. Relationship between drug resistance and HIV-1 disease progression or death in patients undergoing resistance testing , 2004, AIDS.
[23] A. Levy,et al. Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy. , 2004, The Journal of infectious diseases.
[24] Bruno Ledergerber,et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.
[25] S. Deeks,et al. Treatment of antiretroviral-drug-resistant HIV-1 infection , 2003, The Lancet.
[26] Gary Collins,et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.
[27] R. Grant,et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. , 2000, The Journal of infectious diseases.
[28] R. Chaisson,et al. Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions , 1999, Annals of Internal Medicine.